NGS panel for lung cancer

Finding the right cancer treatment
for each patient

Therapy selection in lung cancer patients is critical to achieving the best outcomes. Our targeted lung cancer panel assesses for mutations in eight genes, and rearrangements in four genes, including those recommended by the National Comprehensive Cancer Network: EGFR, ROS1, BRAF, and ALK. The results of this panel ensure that physicians have the information they need to target therapy for their patient. This genetic information also can be useful in prognosis. 

Which test should I order?

A Test in Focus

Kevin Halling, M.D., gives an overview of the lung cancer targeted gene panel. He discusses when this testing should be ordered, how this testing compares to other testing approaches, and what clinical action can be taken due to the results of this testing.

More answers for
more patients

Lung cancer specimens are small and can vary in tumor content. Obtaining enough tissue for multiple molecular and histological tests has historically created a significant challenge for pathologists in testing patients for clinically actionable mutations as recommended. 

Our lung cancer-specific NGS panel includes only clinically relevant markers, allowing for accurate and timely results. We have optimized specimen requirements by reducing the amount of FFPE tissue and accepting cytology as an alternative specimen type, which allows more patients to receive results. 


Insufficient rate means more results for more patients

Resistance mutation testing

Based on recently released guidelines from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology, patients in relapse after an initial response to EGFR-targeted therapies should be tested for the acquired T790M mutation in the EGFR gene.

Which test should I order?

Learn more about how to order this evaluation at your institution.